Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

June 26, 2019

Study Completion Date

August 31, 2022

Conditions

Psoriatic Arthritis

Interventions

DRUG

BCD-085

120 mg / 2 mL subcutaneously

DRUG

Placebo

2 mL

Trial Locations (3)

1st City Clinical Hospital, Minsk

Chelyabinsk Regional Clinical hospital, Chelyabinsk

North-Western State Medical University n.a. I.I.Mechnikov, Saint Petersburg